Goldman Sachs
PTX

Goldman Sachs’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Goldman Sachs’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$898K – 7412
2014
Q2 		$898K Buy
+10,000
New +$613K ﹤0.01% 4788

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's PTX Position: Q3 2018 in Review

Goldman Sachs sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2018, closing a stake of 15,008 shares — an estimated $36K sold.

Goldman Sachs first reported a position in PTX in Q4 2013 and held it in 18 quarters. The position peaked at $3.24M in Q2 2014. 33 funds tracked by Wall St. Rank hold PTX as of Q3 2018.

  • Goldman Sachs reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2018 after selling out during the quarter.
  • Goldman Sachs sold 15,008 Pernix Therapeutics Holdings, Inc. shares in Q3 2018, an estimated $36K.
  • Goldman Sachs first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2013 and held it in 18 quarters.
  • Goldman Sachs's Pernix Therapeutics Holdings, Inc. position peaked at $3.24M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2018.

Based on Goldman Sachs's 13F filing for Q3 2018, filed 14 Nov 2018.